Trial Profile
A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs NDV 3 (Primary)
- Indications Candidiasis; Staphylococcal infections
- Focus Pharmacodynamics
- 22 Jun 2020 Status changed from completed to discontinued.
- 10 Oct 2018 Status changed from active, no longer recruiting to completed.
- 11 May 2018 Planned primary completion date changed from 22 Apr 2018 to 22 Jul 2018.